134 related articles for article (PubMed ID: 32886898)
1. Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis.
Yang JD; Luu M; Singal AG; Noureddin M; Kuo A; Ayoub WS; Sundaram V; Kotler H; Kim IK; Todo T; Voidonikolas G; Brennan TV; Kosari K; Klein AS; Hendifar A; Lu SC; Nissen NN; Gong J
J Natl Compr Canc Netw; 2020 Sep; 18(9):1210-1220. PubMed ID: 32886898
[TBL] [Abstract][Full Text] [Related]
2. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.
Serper M; Taddei TH; Mehta R; D'Addeo K; Dai F; Aytaman A; Baytarian M; Fox R; Hunt K; Goldberg DS; Valderrama A; Kaplan DE;
Gastroenterology; 2017 Jun; 152(8):1954-1964. PubMed ID: 28283421
[TBL] [Abstract][Full Text] [Related]
3. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.
Uhlig J; Sellers CM; Stein SM; Kim HS
Eur Radiol; 2019 May; 29(5):2679-2689. PubMed ID: 30560364
[TBL] [Abstract][Full Text] [Related]
4. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation.
Lao OB; Weissman J; Perkins JD
Clin Transplant; 2009; 23(6):874-81. PubMed ID: 19453644
[TBL] [Abstract][Full Text] [Related]
5. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.
Rich NE; Hester C; Odewole M; Murphy CC; Parikh ND; Marrero JA; Yopp AC; Singal AG
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):551-559.e1. PubMed ID: 29859983
[TBL] [Abstract][Full Text] [Related]
6. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Zhang X; El-Serag HB; Thrift AP
Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
8. Factors that affect risk for hepatocellular carcinoma and effects of surveillance.
Yang JD; Harmsen WS; Slettedahl SW; Chaiteerakij R; Enders FT; Therneau TM; Orsini L; Kim WR; Roberts LR
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):617-23.e1. PubMed ID: 21459158
[TBL] [Abstract][Full Text] [Related]
9. Medicaid and Uninsured Hepatocellular Carcinoma Patients Have More Advanced Tumor Stage and Are Less Likely to Receive Treatment.
Wang J; Ha J; Lopez A; Bhuket T; Liu B; Wong RJ
J Clin Gastroenterol; 2018; 52(5):437-443. PubMed ID: 28723861
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Kuo MJ; Mo LR; Chen CL
BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
[TBL] [Abstract][Full Text] [Related]
11. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
12. Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma.
Scaglione S; Adams W; Caines A; Devlin P; Mittal S; Singal AG; Parikh ND
Dig Dis Sci; 2020 Jun; 65(6):1669-1678. PubMed ID: 31643036
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact.
Govalan R; Luu M; Lauzon M; Kosari K; Ahn JC; Rich NE; Nissen N; Roberts LR; Singal AG; Yang JD
Hepatol Commun; 2022 Jan; 6(1):223-236. PubMed ID: 34558830
[TBL] [Abstract][Full Text] [Related]
15. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States.
Davila JA; Duan Z; McGlynn KA; El-Serag HB
J Clin Gastroenterol; 2012 Jan; 46(1):71-7. PubMed ID: 22157221
[TBL] [Abstract][Full Text] [Related]
16. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
El-Serag HB; Siegel AB; Davila JA; Shaib YH; Cayton-Woody M; McBride R; McGlynn KA
J Hepatol; 2006 Jan; 44(1):158-66. PubMed ID: 16290309
[TBL] [Abstract][Full Text] [Related]
17. Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay Among Patients With Hepatocellular Carcinoma in the United States.
Wagle NS; Park S; Washburn D; Ohsfeldt RL; Rich NE; Singal AG; Kum HC
Clin Gastroenterol Hepatol; 2023 May; 21(5):1281-1292.e10. PubMed ID: 35933076
[TBL] [Abstract][Full Text] [Related]
18. Utilization of screening for hepatocellular carcinoma in the United States.
Davila JA; Weston A; Smalley W; El-Serag HB
J Clin Gastroenterol; 2007 Sep; 41(8):777-82. PubMed ID: 17700427
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.
van Meer S; van Erpecum KJ; Sprengers D; Coenraad MJ; Klümpen HJ; Jansen PL; IJzermans JN; Verheij J; van Nieuwkerk CM; Siersema PD; de Man RA
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):352-9. PubMed ID: 26629867
[TBL] [Abstract][Full Text] [Related]
20. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
